AstraZeneca Acquires Modella AI to Accelerate Oncology R&D with Foundation Models

Summary

AstraZeneca announced the acquisition of Modella AI, a Boston-based firm specializing in AI-driven pathology and biomarker discovery, at the J.P. Morgan Healthcare Conference on January 14, 2026. The deal expands a multi-year collaboration (initiated July 2025) into a full acquisition, with AstraZeneca integrating Modella's multi-modal AI foundation models and AI agents directly into its oncology research organization. AstraZeneca described this as the first acquisition of an AI firm by a major